IPW
AXSM icon

Impact Partnership Wealth’s Axsome Therapeutics AXSM Stock Holding History

Impact Partnership Wealth’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,822
Closed -$333K – 371
2025
Q4 		$333K Buy
+1,822
New +$254K 0.04% 264
2023
Q3 		– Sell
-15
Closed -$1.08K – 1017
2023
Q2 		$1.08K Buy
+15
New +$1.11K ﹤0.01% 785

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Impact Partnership Wealth's AXSM Position: Q1 2026 in Review

Impact Partnership Wealth sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 1,822 shares — an estimated $333K sold.

Impact Partnership Wealth first reported a position in AXSM in Q2 2023 and held it in 2 quarters. The position peaked at $333K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Impact Partnership Wealth reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Impact Partnership Wealth sold 1,822 Axsome Therapeutics shares in Q1 2026, an estimated $333K.
  • Impact Partnership Wealth first reported a position in Axsome Therapeutics in Q2 2023 and held it in 2 quarters.
  • Impact Partnership Wealth's Axsome Therapeutics position peaked at $333K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Impact Partnership Wealth's 13F filing for Q1 2026, filed 23 Apr 2026.